Role of Metformin in the Diagnosis, Prevention, and Treatment of Hepatocellular Carcinoma

Overview

Journal Zhong Nan Da Xue Xue Bao Yi Xue Ban

Specialty General Medicine

Date 2022 May 11

PMID 35545330

Authors

Shize Xiong

Wei Liu

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma is one of the most common malignant tumors in the world. Although there are many options for the treatment of hepatocellular carcinoma, such as surgical resection, interventional therapy, radiotherapy, chemotherapy, targeted therapy and liver transplantation, the poor therapeutic effect seriously reduces the quality of life for patients and also increases the social and economic burden. Metformin is originally used as the first-line drug for type 2 diabetes, but it has been found to play a certain effect in the prevention and treatment of malignant tumor. The potential roles of metformin against hepatocellular carcinoma, such as regulation of the microenvironment, proliferation signal pathway, metabolism, invasion and metastasis, apoptosis, autophagy, and epigenetics of hepatoma cells. It provides a new choice for the prevention and treatment of hepatocellular carcinoma.

Citing Articles

Preliminary Study on Pharmacokinetics and Antitumor Pharmacodynamics of Folic Acid Modified Crebanine Polyethyleneglycol-Polylactic Acid Hydroxyacetic Acid Copolymer Nanoparticles.

Cheng X, Pan R, Tang J, Yu K, Zhang H, Zhao X Int J Nanomedicine. 2024; 19:10513-10536.

PMID: 39435040 PMC: 11492913. DOI: 10.2147/IJN.S477027.

References

Zhou J, Han S, Qian W, Gu Y, Li X, Yang K . Metformin induces miR-378 to downregulate the CDK1, leading to suppression of cell proliferation in hepatocellular carcinoma. Onco Targets Ther. 2018; 11:4451-4459. PMC: 6074828. DOI: 10.2147/OTT.S167614. View

Ling S, Song L, Fan N, Feng T, Liu L, Yang X . Combination of metformin and sorafenib suppresses proliferation and induces autophagy of hepatocellular carcinoma via targeting the mTOR pathway. Int J Oncol. 2016; 50(1):297-309. DOI: 10.3892/ijo.2016.3799. View

Zhang H, Gao C, Fang L, Zhao H, Yao S . Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis. Scand J Gastroenterol. 2012; 48(1):78-87. DOI: 10.3109/00365521.2012.719926. View

Sun R, Zhai R, Ma C, Miao W . Combination of aloin and metformin enhances the antitumor effect by inhibiting the growth and invasion and inducing apoptosis and autophagy in hepatocellular carcinoma through PI3K/AKT/mTOR pathway. Cancer Med. 2019; 9(3):1141-1151. PMC: 6997051. DOI: 10.1002/cam4.2723. View

Yang X, Sun D, Tian Y, Ling S, Wang L . Metformin sensitizes hepatocellular carcinoma to arsenic trioxide-induced apoptosis by downregulating Bcl2 expression. Tumour Biol. 2014; 36(4):2957-64. DOI: 10.1007/s13277-014-2926-5. View

Cunha V, Cotrim H, Rocha R, Carvalho K, Lins-Kusterer L . Metformin in the prevention of hepatocellular carcinoma in diabetic patients: A systematic review. Ann Hepatol. 2019; 19(3):232-237. DOI: 10.1016/j.aohep.2019.10.005. View

Singh S, Paul Singh P, Singh A, Murad M, Sanchez W . Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol. 2013; 108(6):881-91. DOI: 10.1038/ajg.2013.5. View

Vacante F, Senesi P, Montesano A, Paini S, Luzi L, Terruzzi I . Metformin Counteracts HCC Progression and Metastasis Enhancing KLF6/p21 Expression and Downregulating the IGF Axis. Int J Endocrinol. 2019; 2019:7570146. PMC: 6350585. DOI: 10.1155/2019/7570146. View

Chaffer C, Weinberg R . A perspective on cancer cell metastasis. Science. 2011; 331(6024):1559-64. DOI: 10.1126/science.1203543. View

10.

Zhou X, Chen J, Yi G, Deng M, Liu H, Liang M . Metformin suppresses hypoxia-induced stabilization of HIF-1α through reprogramming of oxygen metabolism in hepatocellular carcinoma. Oncotarget. 2015; 7(1):873-84. PMC: 4808039. DOI: 10.18632/oncotarget.6418. View

11.

Tseng C . Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes. Liver Int. 2018; 38(11):2018-2027. DOI: 10.1111/liv.13872. View

12.

Jiang Z, Liu H . Metformin inhibits tumorigenesis in HBV-induced hepatocellular carcinoma by suppressing HULC overexpression caused by HBX. J Cell Biochem. 2017; 119(6):4482-4495. DOI: 10.1002/jcb.26555. View

13.

Ferretti A, Hidalgo F, Tonucci F, Almada E, Pariani A, Larocca M . Metformin and glucose starvation decrease the migratory ability of hepatocellular carcinoma cells: targeting AMPK activation to control migration. Sci Rep. 2019; 9(1):2815. PMC: 6391381. DOI: 10.1038/s41598-019-39556-w. View

14.

Zhao D, Long X, Lu T, Wang T, Zhang W, Liu Y . Metformin decreases IL-22 secretion to suppress tumor growth in an orthotopic mouse model of hepatocellular carcinoma. Int J Cancer. 2014; 136(11):2556-65. DOI: 10.1002/ijc.29305. View

15.

Hagberg K, McGlynn K, Sahasrabuddhe V, Jick S . Anti-diabetic medications and risk of primary liver cancer in persons with type II diabetes. Br J Cancer. 2014; 111(9):1710-7. PMC: 4453721. DOI: 10.1038/bjc.2014.447. View

16.

Saito T, Chiba T, Yuki K, Zen Y, Oshima M, Koide S . Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells. PLoS One. 2013; 8(7):e70010. PMC: 3726625. DOI: 10.1371/journal.pone.0070010. View

17.

Lee M, Hsu C, Wahlqvist M, Tsai H, Chang Y, Huang Y . Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer. 2011; 11:20. PMC: 3031263. DOI: 10.1186/1471-2407-11-20. View

18.

Zhang Q, Kong J, Dong S, Xu W, Sun W . Metformin exhibits the anti-proliferation and anti-invasion effects in hepatocellular carcinoma cells after insufficient radiofrequency ablation. Cancer Cell Int. 2017; 17:48. PMC: 5404300. DOI: 10.1186/s12935-017-0418-6. View

19.

Qu H, Yang X . Metformin inhibits angiogenesis induced by interaction of hepatocellular carcinoma with hepatic stellate cells. Cell Biochem Biophys. 2014; 71(2):931-6. DOI: 10.1007/s12013-014-0287-8. View

20.

Hu L, Zeng Z, Xia Q, Liu Z, Feng X, Chen J . Metformin attenuates hepatoma cell proliferation by decreasing glycolytic flux through the HIF-1α/PFKFB3/PFK1 pathway. Life Sci. 2019; 239:116966. DOI: 10.1016/j.lfs.2019.116966. View